UNSPSC 51283961: Glucosulfamide

This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X40L29981F. European Medicines Agency schedules Glucosulfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07938MIG. Glucosulfamide generally arises in the molecular formula C13H21N2O11S2.NA. The term GLUCOSULFAMIDE is an International Non-Proprietary Name or INN.

GLUCOSULFAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: S(=O)(=O)(O)C(NC1CCC(S(=O)(=O)NCO)CC1)C(O)C(O)C(O)C(O)CO.[NA].

UNSPSC 51283961 Glucosulfamide, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The code does not appear in current solicitations from state and local agencies; the two posted opportunities in the source relate to pharmaceutical warehouse piggyback orders and naloxone procurement, neither of which involves glucosulfamide as a line item or primary product.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride), and Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems. Neither procurement directly engages the glucosulfamide commodity. Without recent open solicitations explicitly naming glucosulfamide as a deliverable or line item, the code signals limited near-term pursuit opportunity under current state and local pharmaceutical procurement patterns.